UTHR Financial Facts
Diluted (in shares): 46.2MResearch and development: 45.9M
See Full Income Statement
Commitments and contingencies:: 0
Total liabilities: 419.6M
See Full Balance Sheet
United Therapeutics Corp. (UTHR) Earnings
|
Expand Research on UTHR
| Next EPS Date | 5/1/24 | EPS Growth Rate | +19.1% |
|---|---|---|---|
| Average EPS % Beat Rate | +6.1% | Revenue Growth Rate | +22.7% |
| Average % Move 1-Wk after EPS | -0.1% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 8/4/21 | Q221 | $4.09 | $3.02 | +$1.07 | $446.5M | $378.75M | N/A |  | | Details | |
| 11/2/22 | Q322 | $4.91 | $4.06 | +$0.85 | $516M | $493.81M | N/A | | | Details | |
10/27/15  |
 |
Q315 | $3.55 | $2.35 | +$1.20 | $386.2M | $363.5M | N/A | | | Details |
| 7/29/14 |
|
Q214 | $2.57 | $1.75 | +$0.82 | $322.8M | $308.04M | N/A | | | Details |
| 10/28/20 | |
Q320 | $3.88 | $2.78 | +$1.10 | $380.1M | $356.95M | N/A | | | Details |
| 11/3/21 | |
Q321 | $4.16 | $3.59 | +$0.57 | $444.7M | $421.45M | N/A | | | Details |
| 10/30/19 | |
Q319 | $3.83 | $2.47 | +$1.36 | $401.5M | $337.6M | N/A | | | Details |
| 5/4/22 | |
Q122 | $5.03 | $3.34 | +$1.69 | $461.9M | $420.02M | N/A | | | Details |
